Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002405 · ClinicalTrials.gov registry record · NA
A Study of Amprenavir in HIV-Infected Patients
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00002405: Completed NA study, sponsored by Glaxo Wellcome.
NCT00002405 is a NA study that has completed, run by Glaxo Wellcome. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002405, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The purpose of this study is to see if it is safe to give amprenavir (APV) to HIV-infected patients. This study also examines the effect APV has on the level of HIV in the blood. Earlier studies have shown that APV is effective in slowing the growth of HIV in the body. Patients who have failed previous anti-HIV treatment or who are unable to take other protease inhibitors (PIs) may benefit from the availability of a new PI such as APV.
Interventions
- DRUG Amprenavir
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002405 record still lists
NCT00002405 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Amprenavir is the first listed.
NCT00002405 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002405 about?
NCT00002405 is a clinical study titled "A Study of Amprenavir in HIV-Infected Patients". The purpose of this study is to see if it is safe to give amprenavir (APV) to HIV-infected patients. This study also examines the effect APV has on the level of HIV in the blood. Earlier studies have shown that APV is effective in slowing the growth of HIV in the body. Patients who have failed prev...
What is the current status of trial NCT00002405?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002405?
The interventions under investigation include: Amprenavir (DRUG).
Who is sponsoring clinical trial NCT00002405?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.